As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands.

The focussed, two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Further sessions explore the use of automation to augment drug development and improve your lab productivity, showcasing the competitive advantages that can be gained in drug development through digitalization and robotics.

Event link here.